Journal: Cell Reports

Article Title: HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients

doi: 10.1016/j.celrep.2017.05.078

Figure Lengend Snippet: HSP90-Dependent Degradation of eYFP-CRAF Fusion Protein (A) eYFP-CRAF stably transfected into HEK293 retains the cytoplasmic distribution displayed by endogenous CRAF. Scale bar, 50 μm. (B) eYFP-CRAF transfected into HEK293 expresses a stable full-length protein with no detectable free eYFP, so that all cellular fluorescence can be attributed to levels of the fusion protein. (C) eYFP-CRAF, like endogenous CRAF, is degraded in HEK293 cells following treatment with the HSP90 ATPase inhibitor AUY922. (D) Treatment of transfected cells with AUY922 promotes ubiquitylation of eYFP-CRAF, as visualized in an anti-ubiquitin western blot. The levels of ubiqutylated protein detected are enhanced by the proteasome inhibitor MG132. These data confirm that eYFP-CRAF is degraded in the same way as previously shown for endogenous CRAF. (E) Treatment of transfected cells with AUY922 over 8 hr gives an ∼50% reduction in relative fluorescence intensity of transfected cells compared with untreated cells. Error bars show SD.

Article Snippet: Primary antibodies used were: α-CRAF (SC-133 or SC-7267, Cell Signaling), α-HECTD3 (ab173122, Abcam), and HSP90 (ab13492, Abcam).

Techniques: Stable Transfection, Transfection, Fluorescence, Ubiquitin Proteomics, Western Blot

Journal: Cell Reports

Article Title: HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients

doi: 10.1016/j.celrep.2017.05.078

Figure Lengend Snippet: siRNA Screen for Factors Mediating eYFP-CRAF Degradation (A) Waterfall plot of siRNA-targeted genes (horizontal) versus the stabilization of fluorescence in cells expressing eYFP-CRAF transfected with test siRNAs and treated with AUY922 relative to treated cells transfected with a control siRNA. (B) Repeat siRNA knockdowns of “hits” identified in (A); knockdown of HECTD3, CUL5, and UBA1 (also known as UBE1) using different siRNAs from those in (A) gave robust and reproducible stabilization of eYFP-CRAF on AUY922 treatment. Measurements are averages of four (UBA1 only) or six replicates, and error bars indicate SD. Stabilization relative to control following knockdown of HECTD3, CUL5, and UBA1 is significant in a paired t test (p < 0.0001 for HECTD3 and CUL5, and p = 0.001 for UBA1). (C) Same as in (B), but comparing the siRNA knockdown of CUL5 (same data as in B) with the knockdown of known CUL5 CRL complex components, relative to siRNA control. Knockdown of the accessory scaffold components TCEB1 (also known as Elongin C) and TCEB2 (also known as Elongin B) stabilized eYFP-CRAF to a degree comparable to that of CUL5 (p = 0.00015 for TCEB1, and p = 0.00017 for TCEB2), consistent with their essential involvement in CUL5-based CRL E3 ligase complexes. However, none of the SOCS proteins gave comparable stabilization (all significant measurements at least p < 0.01). Values are averages of six replicates and error bars show SD.

Article Snippet: Primary antibodies used were: α-CRAF (SC-133 or SC-7267, Cell Signaling), α-HECTD3 (ab173122, Abcam), and HSP90 (ab13492, Abcam).

Techniques: Fluorescence, Expressing, Transfection, Control, Knockdown

Journal: Cell Reports

Article Title: HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients

doi: 10.1016/j.celrep.2017.05.078

Figure Lengend Snippet: Kinase Specificity of HECTD3 (A) Western blot of endogenous CRAF in HEK293 cell lysates following 24-hr treatment with AUY922. Substantial degradation is observed in cells transfected with control siRNA, but CRAF levels are stabilized in cells transfected with siRNA against HECTD3. Both immunoreactive bands to the HECTD3 antibody are knocked down by the siRNA; see below. GAPDH levels provide a loading control. (B) Western blots of known HSP90 protein kinase clients in HEK293 lysates and their response to treatment of cells with AUY922. Levels of ErbB2, MASTL, CRAF, LKB1, and CDK4, but not BRAF or PDK1, decrease in response to HSP90 inhibition. (C) MASTL, LKB1, and CRAF degradation following AUY922 treatment is reduced in HEK293 cells transfected with siRNA to HECTD3 compared to a control siRNA. Knockdown of HECTD3 had no clear effect on AUY922-triggered degradation of ErbB2 or CDK4. The panel is a montage of three separate experiments; GAPDH is a loading control for each. (D) Western blot of eYFP-CRAF immunoprecipitated from cell lysates of HEK293 cells treated with increasing doses of AUY922 post-lysis. Ubiquitylation of eYFP-CRAF can be enhanced in HEK293 cell lysates, as well as in intact cells, by the addition of AUY922 in a dose-dependent fashion.

Article Snippet: Primary antibodies used were: α-CRAF (SC-133 or SC-7267, Cell Signaling), α-HECTD3 (ab173122, Abcam), and HSP90 (ab13492, Abcam).

Techniques: Western Blot, Transfection, Control, Inhibition, Knockdown, Immunoprecipitation, Lysis

Journal: Cell Reports

Article Title: HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients

doi: 10.1016/j.celrep.2017.05.078

Figure Lengend Snippet: Cellular Association of HSP90, CRAF, and HECTD3 (A) Combined differential interference contrast (Nomarski)/fluorescence image of field of untreated HEK293 cells. Cell nuclei are indicated in blue (DAPI), and co-localized HSP90 and CRAF are visualized as red foci generated by a rolling circle amplification PLA (see ). Scale bars, 50 μm. Right panel shows a 5× digital zoom of the left panel. (B) Histogram of average PLA foci per cell from analysis of cells before and after treatment with AUY922 for the protein pairs indicated ( Figure S3 ). Proximity of eYFP and endogenous HSP90 was measured in cells expressing eYFP and provides a control for the non-specific signal; all other measurements were in un-transfected HEK293 cells. Values are averages of eight fields and error bars show SD; ∗ p > 0.05; ∗∗ p ≤ 0.01; ∗∗∗∗ p ≤ 0.0001. (C) Western blot of immunoprecipitated eYFP-CRAF from HEK293 cells showing co-immunoprecipitation of HECTD3. The levels of recovered HECTD3 diminish as eYFP-CRAF is degraded following treatment with AUY922. (D) Western blots of HSP90, CRAF, and CDC37 co-immunprecipitated from HEK293 cells expressing eYFP-HECTD3, HECTD3-eYFP, or eYFP, with GFP-trap (see ). Levels of HSP90 and CDC37 co-immunoprecipitated with the HECTD3 constructs increase with length of drug exposure. No HSP90 CRAF or CDC37 was co-immunoprecipitated from cells expressing eYFP only. The levels of recovered CRAF diminish as it is degraded following treatment with AUY922. GFP immunoreactivity provides a common loading control. See also Figure S3 .

Article Snippet: Primary antibodies used were: α-CRAF (SC-133 or SC-7267, Cell Signaling), α-HECTD3 (ab173122, Abcam), and HSP90 (ab13492, Abcam).

Techniques: Fluorescence, Generated, Amplification, Expressing, Control, Transfection, Western Blot, Immunoprecipitation, Construct

Journal: Cell Reports

Article Title: HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients

doi: 10.1016/j.celrep.2017.05.078

Figure Lengend Snippet: The DOC Domain of HECTD3 Mediates Substrate Interaction (A) Schematic of the domain architecture of HECTD3. Only two defined domains can be recognized: the C-terminal catalytic HECT domain common to all members of the HECT E3 ubiquitin ligase family and a DOC domain homologous to APC10, which occurs midway through the N-terminal region. (B) Coomassie-stained SDS-PAGE of purified recombinant HECTD3 constructs: His 6 -tagged full-length HECTD3 and GST fusions of the isolated DOC and HECT domains. M, molecular weight, in kilodaltons. (C) Top: lysates from HEK293 cells expressing either eYFP or eYFP-CRAF were incubated with purified HECTD3 constructs as in (A), subjected to immunoprecipitation using GFP-Trap , and analyzed by western blot using α-His (left) or α-GST (right). Full-length HECTD3 and the isolated DOC domain, but not the isolated HECT domain, were co-immunoprecipitated from eYPF-CRAF cells. Bottom: loading control for above, western blotted with α-GFP. (D) Purified GST-DOC was added to HEK293 lysates treated with increasing concentrations of the HSP90 inhibitor AUY922 from 0, 100, 200, 400, 800, 1,600, and 3,200 nM and immunoprecipitated. Endogenous CRAF and HSP90 were co-immunoprecipitated, with increased yields at the higher drug concentrations.

Article Snippet: Primary antibodies used were: α-CRAF (SC-133 or SC-7267, Cell Signaling), α-HECTD3 (ab173122, Abcam), and HSP90 (ab13492, Abcam).

Techniques: Ubiquitin Proteomics, Staining, SDS Page, Purification, Recombinant, Construct, Isolation, Molecular Weight, Expressing, Incubation, Immunoprecipitation, Western Blot, Control

Journal: Cell Reports

Article Title: HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients

doi: 10.1016/j.celrep.2017.05.078

Figure Lengend Snippet: HECTD3 Is Downregulated in Cancer Cell Lines with Activated MAPK Signaling (A) Western blot of HECTD3 in lysates from HEK293, COS7, and four human cancer cells lines: U2OS, HT29, HCT116, and A549. Tumor cell lines either lack immunoreactive protein or express a truncated isoform (also visible in HEK293) that is recognized by the C-terminal epitope of the α-HECTD3 antiserum. The molecular weight of the truncated product corresponds to that predicted for an experimentally documented, alternatively spliced isoform of HECTD3. (B) Western blot of HECTD3 from lysates of HEK293 cells expressing eYFP-CRAF. While both 97-kDa and 65-kDa HECTD3 isoforms are present in the input, only the 97-kDa species corresponding to the full-length protein is co-immunprecipitated with eYFP-CRAF. (C) The truncated splice isoform of HECTD3 in HCT116 cells is effectively knocked down by siRNA, but unlike knockdown of the full-length protein in HEK293 cells, this does not stabilize endogenous CRAF protein to degradation triggered by AUY922. This shows that the 65-kDa isoform is not an active participant in CRAF ubiquitylation and degradation.

Article Snippet: Primary antibodies used were: α-CRAF (SC-133 or SC-7267, Cell Signaling), α-HECTD3 (ab173122, Abcam), and HSP90 (ab13492, Abcam).

Techniques: Western Blot, Molecular Weight, Expressing, Knockdown

Journal: International Journal of Biological Sciences

Article Title: USP25 stabilizes STAT6 to promote IL-4-induced macrophage M2 polarization and fibrosis

doi: 10.7150/ijbs.99345

Figure Lengend Snippet: USP25 inhibit K48 ubiquitination of STAT6 to enhance STAT6/PPAR-γ signaling in macrophages. (A) Upper panel: representative Western blot results for STAT6, PPAR-γ and SOCS3 at different time points stimulated with IL-4. Lower panel: figures showing the data with three mice analyzed. (B) Western blot analysis of SOCS3 in the lung homogenates. (C) USP25 did not affect MAPK (p38 and ERK), Akt and PI3K signaling. (D) Upper panel: immunoprecipitation of proteins using USP25 antibody and immunoblotting analysis using STAT6 antibody. Lower panel: immunoprecipitation of proteins using STAT6 antibody and immunoblotting analysis using USP25 antibody. (E) BMDMs of WT and USP25 -/- were treated with MG132 (10 μM) for 6 h before lysis, followed by stimulation of IL-4 (10 ng/mL) for 30 min. Proteins were immunoprecipitated with STAT6 antibody and analyzed by immunoblotting with the indicated antibodies. (F) NIH/3T3 cells were transfected with plasmids encoding the indicated constructs. Proteins were immunoprecipitated with anti-STAT6 antibody and analyzed by immunoblotting with the indicated antibodies. IP, immunoprecipitation; STAT6, signal transducer and activator of transcription 6; PPAR-γ, peroxisome proliferator-activated receptor gamma; SOCS3, suppressor of cytokine signaling 3. *p < 0.05 and **p < 0.01.

Article Snippet: Primary antibodies include anti-STAT6 antibody (Cat:380957, ZENBIO, China), anti PPAR-γ antibody (Cat: A11183, ABCLONAL, China), anti-USP25 antibody (Cat: ab187156, Abcam, USA), anti-Arg1 antibody (Cat: ab91279, Abcam, USA), anti-Ubi antibody (Cat: 134953, Abcam, USA), anti-Ub-k48 antibody (Cat: 140601, Abcam, USA).

Techniques: Ubiquitin Proteomics, Western Blot, Immunoprecipitation, Lysis, Transfection, Construct